Earthquake : A powerful 7.1 EQ rocks the Island of Bohol in the Philippine Islands (Oct 15, 2013) – Video

Posted on by


Earthquake : A powerful 7.1 EQ rocks the Island of Bohol in the Philippine Islands (Oct 15, 2013)
SOURCE: http://www.bbcnews.com News Articles: At least 20 people killed after 7.2 earthquake hits central Philippines http://www.foxnews.com/world/2013/10/14...

By: SignsofThyComing

See original here:

Earthquake : A powerful 7.1 EQ rocks the Island of Bohol in the Philippine Islands (Oct 15, 2013) - Video

Construction rebounds on barrier islands

Posted on by

Published: Wednesday, October 16, 2013 at 2:12 p.m. Last Modified: Wednesday, October 16, 2013 at 2:12 p.m.

New home construction on Southwest Florida's barrier islands hardly took a breath during the Great Recession, but the economic recovery has sparked a new burst of activity.

Unlike larger housing developments on the mainland that were shelved during the downturn, some for years, many builders of custom luxury homes continued to find work though at a much slower pace on the region's keys.

"We definitely went through a slow time, but not nearly as bad as the tract home builders," said Ricky Perrone, vice president of business development at Sarasota's Perrone Construction.

For Perrone, business began to bounce back about a year ago. The company is currently building six custom homes on Siesta, Lido and Bird keys, valued from $1.7 million to $3 million and ranging from from 4,000 square feet to 8,000 square feet.

"Things really picked up last October," Perrone said. "People were getting off the fence and moving on big properties where they planned homes. Properties started to get snatched up, and people decided the time was right to build."

Lakewood Ranch-based John Cannon Homes is in various stages of construction on 12 custom homes on the barrier islands off Sarasota and Manatee counties.

"The barrier island buyer has been shown to be recession proof," said the company's namesake.

Sarasota's Murray Homes has four custom projects under way on the islands, ranging from $850,000 to $2.5 million and measuring from 3,000 square feet to 7,000 square feet.

"That's based on how comfortable individuals feel with the economy and their own personal situation," said Steve Murray, vice president at the family owned company. "They have recouped losses from the recession, reallocated investments and are now feeling comfortable enough to jump in and buy.

See more here:

Construction rebounds on barrier islands

Angiochem to Present at the American Society of Human Genetics 2013 Annual Meeting

Posted on by

MONTREAL--(BUSINESS WIRE)--

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced that an abstract on its Angiopep-2 (An2) conjugate technology has been selected for presentation at the American Society of Human Genetics (ASHG) 2013 Annual Meeting being held October 22-26, 2013 in Boston, Massachusetts.

These data demonstrate the ability of Angiochem technology to create proteins that can access the CNS; a key attribute for enzyme replacement therapy, commented Jean E. Lachowicz, Ph.D., Chief Scientific Officer of Angiochem Inc. We are applying this approach to an enzyme associated with mucopolysaccharidosis to create a brain-penetrant enzyme replacement therapy that will address neurological symptoms.

Poster Presentation:

(Abstract/Poster #2288F): Friday, October 25, 2013, 11:30-12:30 p.m. ET, Fusion with Angiopep-2 to create proteins that cross the blood-brain barrier and are taken up into cells, Jean E. Lachowicz, Ph.D., Therapy for Genetic Disorders Session, Convention Center, Exhibit Hall, Level 1.

About Angiochem

Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathwayto cross the BBB to treat neurological diseases. These new compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB.

Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including primary brain cancer, brain metastases, lysosomal storage diseases and pain. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit http://www.angiochem.com.

Here is the original post:

Angiochem to Present at the American Society of Human Genetics 2013 Annual Meeting

Rosetta Genomics' Announces Poster Presentation at the American Society of Human Genetics Annual Meeting 2013

Posted on by

PRINCETON, NJ and REHOVOT, ISRAEL--(Marketwired - Oct 17, 2013) - Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company's Cancer Origin Test will be highlighted in a poster presentation at the upcoming American Society of Human Genetics Annual Meeting 2013 (ASHG 2013) taking place October 22-26 at the Boston Convention and Exhibition Center in Boston, Mass.

Poster presenters will be available October 23rd from 10:30 a.m. to 12:00 p.m., and posters will be available for viewing beginning October 23rd at 10:30 a.m. until October 25th at 2:00 p.m. The following poster highlighting Rosetta Genomics' Cancer Origin Test will be presented at ASHG 2013:

Prediction of the risk of cancer in families, genetic testing, counseling and other options are heavily dependent upon accurate diagnosis of cancers that have occurred in other family members. When a deceased relative's medical records are incomplete or inaccurate in any way, appropriate counseling and decision-making is impaired. Relatives of patients who die from cancers of unknown or uncertain primary (CUP), which occurs in over 3-5% of all cancers, are particularly challenged in accurately assessing their cancer risk.

Molecular profiling with Rosetta's microRNA-based Cancer Origin Test has been shown to effectively identify the underlying tumor type in CUP cases, and allows for more accurate identification of potentially unrecognized genetic risks, or the correct assessment when risk might otherwise have been over-estimated by the family or their genetic counselors. As microRNA has been shown to be particularly stable in FFPE preserved tumor blocks for over 10-years, archival material analysis of a deceased relative's cancer when CUP or uncertain results confounded a pedigree is now possible with this assay.

The poster presentation highlights a study outlining the findings in a population of deceased CUP patients. The study demonstrated the frequency with which the results might impact the cancer risk assessment in their family if this test were not utilized to resolve the uncertainty of the actual cancer diagnosis of the deceased CUP patient. The study concluded that, "microRNA profiling in CUP patients has an incrementally important clinical utility in uncovering previously unknown or inaccurate genetic risks associated with specific cancer diagnoses in at least one-third of cases, potentially directing specific genetic testing for relatives."

"The Cancer Origin Test may be of importance in clarifying the disease pedigree for families with a history of CUP seeking information on their genetic risk of cancer. Our findings showed a high frequency of breast, ovarian and colon cancers, including significant numbers of male breast cancers in the CUP population, which clearly indicates that pedigrees with unresolved diagnoses from CUP cases could be highly informative if the Cancer Origin Test is applied," said Dr. Wassman. "In addition, our identification of exceedingly rare cancers with high genetic risks in families further highlights the value of this testing."

About the American Society of Human Genetics Annual MeetingThe ASHG Annual Meeting is the largest human genetics meeting and exposition in the world. ASHG 213 is expected to attract over 6,500 scientific attendees, plus nearly 200 exhibiting companies. ASHG members and leading scientists from around the world are selected to present their research findings at invited, platform, and poster sessions. Abstracts of work submitted for presentation at the Annual Meeting are published online. ASHG's Annual Meeting also features a trade show floor that offers attendees the opportunity to view state-of-the-art medical and laboratory equipment, products, services, and computer software designed to enhance human genetics research, teaching, and consultation.

About Rosetta Cancer Testing Services Rosetta Cancer Tests are a series of microRNA-based diagnostic testing services offered by Rosetta Genomics. The Rosetta Cancer Origin Test can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). The Rosetta Mesothelioma Test diagnoses mesothelioma, a cancer connected to asbestos exposure. The Rosetta Lung Cancer Test accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. The Rosetta Kidney Cancer Test accurately classifies the four most common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and the benign oncocytoma. Rosetta's assays are designed to provide objective diagnostic data; it is the treating physician's responsibility to diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the Cancer Origin Test, 60,000 from the Mesothelioma Test, 65,000 from the Kidney Cancer Test and 226,000 patients from the Lung Cancer Test. The Company's assays are offered directly by Rosetta Genomics in the U.S., and through distributors around the world. For more information, please visit http://www.rosettagenomics.com. Parties interested in ordering the test can contact Rosetta Genomics at (215) 382-9000 ext. 309.

About Rosetta GenomicsRosetta develops and commercializes a full range of microRNA-based molecular diagnostics. Founded in 2000, Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta's cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab. Frost & Sullivan recognized Rosetta Genomics with the 2012 North American Next Generation Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement DisclaimerVarious statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, Rosetta's Cancer of Origin Test, the Cancer Origin Test improving the ability of physicians to accurately diagnose CUP, the Cancer Origin Test's ability to help physicians to optimize treatment, Rosetta's development or commercialization of molecular diagnostics, the market acceptance of Rosetta's cancer testing services, particularly the Cancer Origin Test, the clinical utility of microRNA profiling in CUP patients in uncovering previously unknown or inaccurate genetic risks associated with specific cancer, the possible importance of the Cancer Origin Test in clarifying the pedigree in families seeking information on their genetic risk of cancer and the value of such testing constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2012 as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Go here to see the original:

Rosetta Genomics' Announces Poster Presentation at the American Society of Human Genetics Annual Meeting 2013

City of Akron opening two computer-assisted health care sign-up sites

Posted on by

10/17/2013 - West Side Leader

AKRON As of Oct. 15, the city of Akron has opened two computer-assisted Affordable Care Act (ACA) health care sign-up sites for citizens who do not have computer access or who need help electronically signing up for health care.

The Lawton Street Community Center, 1225 Lawton St. in West Akron, and Firestone Park Community Center, 1480 Girard St. in South Akron, will be open each Tuesday and Thursday (until further notice) from 11 a.m. to 2 p.m. and 3:30 to 6 p.m. Certified application counselors from Summit County Public Health will be at each site to assist residents and to answer any questions.

The Affordable Care Act can help many of our residents, but only if they sign up, said Akron Mayor Don Plusquellic. It is important that our residents get all the assistance they need to sign up for health care coverage under the Affordable Care Act. I am thankful to County Executive Russ Pry and the Summit County Public Health Department for partnering with us to help our citizens.

The city also has information on the new ACA and the Health Insurance Marketplace on its website, http://www.akronohio.gov. From the citys homepage, residents can access the national website, http://www.HealthCare.gov, or Summit County Public Health to obtain online applications. Residents also can call 800-318-2596 to reach the 24-hour, seven-days-a-week national call center where trained customer service representatives will answer all questions about the Health Insurance Marketplace in 150 languages, according to city officials.

The city also is providing a short-form paper application to residents. Those are available at all city of Akron recreation centers and in the lobby of the Municipal Building, 166 S. High St. in Downtown Akron.

CLEVELAND Residents who had been paying fees to the Northeast Ohio Regional Sewer District (NEORSD) will not be paying them now that a judge has ruled against the district.

In the case Northeast Ohio Regional Storm District v. Bath Township, et al, the Ohio 8th District Court of Appeals ruled against NEORSD. In the Sept. 26 ruling, judges said the district does not have the authority to collect fees from residents to fund its storm water projects.

Sewer district officials said they plan to appeal the decision to the Ohio Supreme Court, but in the meantime the fees will be suspended.

View post:

City of Akron opening two computer-assisted health care sign-up sites

Closing of Lake Shore Health Care Center prompts concerns over impact on patients, employees

Posted on by

When Lake Shore Health Care Center in Irving closes Jan. 31, many residents in need of an emergency room will have to drive longer distances for treatment of their medical emergencies, according to a Chautauqua County legislator.

We can measure Lake Shores closing in lost jobs and in peoples lives, said Legislator George Borrello, R-Irving.

Those needing mental health care will have to travel farther, too, but still might struggle to find the help they need.

I am really worried about services that have been provided by the behavioral health unit, said Christine Schuyler, director of the county Department of Health and Human Services.

She said Lake Shores unit has 24 inpatient beds. Another nearby place for inpatient mental health services is at WCA in Jamestown. But patients already fill that facility most of the time, she said.

The residents of the northern area of the county and even Erie County and Cattaraugus County who need mental health services will suffer with the loss of those beds, she said.

Hospital officials announced Lake Shores closing Wednesday, leaving 460 employees without jobs and eliminating one of Chautauqua Countys largest employers.

The facility also has 120 beds for long-term care. The health care center includes an emergency room and a residential program for rehabilitation of womens chemical dependency.

Many people are dependent on the facility, including those in the Seneca Nation, Borrello said.

Patients at Lake Shore at the time of closing will be transferred to Brooks Memorial Hospital in Dunkirk, and those in the program for long-term care will be relocated to other facilities with skilled-nursing services.

More:

Closing of Lake Shore Health Care Center prompts concerns over impact on patients, employees

Health Care Quality Study: Good News, Bad News and in Between

Posted on by

WASHINGTON--(BUSINESS WIRE)--

The National Committee for Quality Assurance (NCQA) will release its analysis of the latest quality results in its State of Health Care Quality Report 2013. Findings include:

The 2013 State of Health Care Quality Report summarizes calendar year 2012 Healthcare Effectiveness Data and Information Set (HEDIS) results from health plans covering 136 million people, or 43 percent of the U.S. population. HEDIS is health cares most widely used performance improvement tool.

WHO:

NCQA President Margaret E. OKane will brief journalists on the report.

-- Joseph V. Agostini, Chief Medical Officer for Medicare Collaborations, Aetna

-- Charles J. Homer, MD, CEO, National Initiative for Children's Healthcare Quality

-- Mark A. Lepage, MD, CEO, Security Health Plan

-- Nora Wells, Co-Director Family Voices National Center for Family Professional Partnerships, Family Voices

WHEN:

Read the original here:

Health Care Quality Study: Good News, Bad News and in Between

Health care exchange problems continue

Posted on by

WASHINGTON - Two weeks into the launch of the federal health insurance exchange, the website is still plagued with problems, leading critics to wonder if the problem is worse than it appears.

There are two key issues at the core of the problem, said Dan Schuyler, a director at Leavitt Partners, a health care group. One is the volume, which Health and Human Services estimates at 14.6 million unique visitors, and the second is the platform's design.

The main problem, Schuyler said, could be "core fundamental design flow," but it's impossible to know because HHS is saying so little. "Only the contractors and HHS know that," he said.

They need to figure out the problem soon, Schuyler said, if the government is to meet its goal of 7 million new health customers signing up on the exchanges by March 31. "That's 39,000 enrolled a day, and we're not seeing anywhere near that volume," Schuyler said. "If they don't get it fixed within two or three weeks, we may have a backlog of consumers who won't be able to enroll by January 1."

HHS didn't have enough time to test its system for "one of the most complex IT platforms undertaken by the feds or the states," Schuyler said.

HHS did not respond to a request for information, and its website states that there are too many media requests now to answer all of them. However, at the end of the first two weeks, HHS issued a statement:

"We won't stop improving HealthCare.gov until its doors are wide open, and at the end of the six-month open enrollment, millions of Americans gain affordable coverage," said HHS spokeswoman Joanne Peters.

President Obama criticized the problems in a Tuesday interview with KCCI, a Des Moines TV station. "I am the first to acknowledge that the website that was supposed to do this all in a seamless way has had way more glitches than I think are acceptable and we've got people working around the clock to do that," he told the Iowa station. "We've seen some significant progress but until it's 100% I'm not going to be satisfied."

Tuesday, Millward Brown Digital released an analysis showing that 36,000 of the 9.47 million people who visited the site the first week made it to the enrollment page at healthcare.gov, with the assumption that only a small percentage of the visitors were able to enroll. HHS has not released enrollment numbers. Millward Brown is an international market-research group.

"I will be the first to tell you that the web site launch was rockier than we wanted it to be,'' HHS Secretary Kathleen Sebelius said Wednesday morning at Cincinnati State Technical and Community College. She did not give an update on numbers, but said people still have plenty of time to enroll before the Dec. 15 deadline for coverage to begin January 1.

Go here to see the original:

Health care exchange problems continue

Coventry Health Care Will Now Offer Medicare Beneficiaries More Choice in More Regions across the United States

Posted on by

BETHESDA, Md.--(BUSINESS WIRE)--

Coventry Health Care today announced the expansion of its Medicare Advantage service area to 26 counties across Louisiana and West Virginia and in 48 additional counties in 16 other states for 2014. The low-cost Medicare Advantage HMO and PPO plans offer beneficiaries more choice for affordable and convenient coverage alternatives with attractive benefits, including $0-premium plans in some areas, low copayments for primary care physician visits and fitness programs.

Coventrys Medicare Advantage plans are some of the highest quality rated plans in the country by the Centers for Medicare & Medicaid Services (CMS),* and are designed to provide members affordable and convenient coverage alternatives. Most plans offer extra benefits not covered under Original Medicare (like prescription drug coverage and comprehensive dental, eyewear and hearing-aid benefits), and several plans offer extras, such as fitness club memberships.

This expansion marks Coventrys commitment to provide Medicare beneficiaries with more benefit options and greater provider choice, said Armando Luna, Jr., vice president, Medicare Marketing and Sales for Coventry Health Care. We are excited about the opportunity to offer more beneficiaries access to convenient, quality health care at prices they can afford.

There are more than 311,000 Coventry Medicare Advantage members in 16 states. For the upcoming 2014 annual enrollment period, Coventry Medicare Advantage plans will be available to seniors in 26 counties across Louisiana and West Virginia and in additional counties throughout Arkansas, Florida, Georgia, Illinois, Iowa, Kansas, Nebraska, North Carolina, Missouri, Ohio, Oklahoma, Pennsylvania, South Dakota, Texas, Utah and Wyoming.

Medicare beneficiaries can enroll in Coventrys 2014 plans during the annual enrollment period, which begins October 15, 2013, and ends December 7, 2013.

Coventry offers several resources to help beneficiaries find the best plan for them. Benefit plans, service areas and a schedule of complimentary education seminars are available at News.MyCoventryMedicare.com.

Coventry expanded its Medicare Advantage service area into the following counties for 2014:

About Coventry Health Care

Coventry Health Care, an Aetna company, provides a full portfolio of risk and fee-based products, including Medicare and Medicaid programs, group and individual health insurance, workers compensation solutions, and network rental services. Coventry Health Care is a Coordinated Care plan with a Medicare contract and a Medicare-approved Part D sponsor. For more information, see http://www.coventryhealthcare.com.

Follow this link:

Coventry Health Care Will Now Offer Medicare Beneficiaries More Choice in More Regions across the United States

The Real Blade Runner: A Conversation with Futurist Syd Mead – Autoline This Week 1732 – Video

Posted on by


The Real Blade Runner: A Conversation with Futurist Syd Mead - Autoline This Week 1732
He started out drawing cars and became a Hollywood sensation. Syd Mead, the inspiration behind the futurist world of the film "Blade Runner" as well as many ...

By: Autoline Network

Originally posted here:

The Real Blade Runner: A Conversation with Futurist Syd Mead - Autoline This Week 1732 - Video

Datawars and the future of Advertising: Futurist Speaker Gerd Leonhard at Guardian Ad Summit (2) – Video

Posted on by


Datawars and the future of Advertising: Futurist Speaker Gerd Leonhard at Guardian Ad Summit (2)
EDITED version (without Guardian intro jingle). Thanks to TheGuardian for making this available via http://www.theguardian.com/media-network/video/2013/oct/0...

By: Gerd Leonhard

More:

Datawars and the future of Advertising: Futurist Speaker Gerd Leonhard at Guardian Ad Summit (2) - Video